BACKGROUND AND PURPOSE: Cerebral microbleeds (CMBs) are a marker of small vessel diseases, including hypertensive arteriopathy and cerebral amyloid angiopathy, and may be associated with cognitive impairment. The relationship between CMBs and cognitive function in ischemic cerebrovascular disease remains uncertain. We, therefore, investigated the cognitive impact of CMBs in a cohort of patients with ischemic stroke or transient ischemic attack. METHODS: All patients underwent detailed and comprehensive neuropsychological testing and standardized MRI, including fluid attenuation inversion recovery, T1, T2, and gradient-recalled echo T2*-weighted sequences. CMBs, white matter changes, lacunes, and territorial cortical infarcts (defined by standardized criteria) were identified, and associations with cognition assessed. RESULTS: Three hundred twenty patients with a diagnosis of ischemic stroke or transient ischemic attack were included. Of these, 72 (22.5%) had at least 1 CMB. Of all the cognitive domains tested, only executive impairment was more prevalent in patients with CMBs than without (38% versus 25%; P=0.039). In univariate analysis, the presence of strictly lobar (but not deep) CMBs was associated with executive impairment (odds ratio, 2.49; 95% confidence interval, 1.16-5.36; P=0.019). In adjusted multivariate analyses, the presence (OR, 2.34; 95% confidence interval, 1.08-5.09; P=0.031) and number (OR, 1.33; 95% confidence interval, 1.04-1.69; P=0.022) of strictly lobar CMBs were significantly associated with executive impairment. CMBs were not associated with impairment in other cognitive domains. CONCLUSIONS: Strictly lobar CMBs are independently associated with executive dysfunction in patients with ischemic stroke or transient ischemic attack. Our findings suggest that a microangiopathy related to strictly lobar CMBs (eg, cerebral amyloid angiopathy) contributes to cognitive impairment in this population.
BACKGROUND AND PURPOSE: Cerebral microbleeds (CMBs) are a marker of small vessel diseases, including hypertensive arteriopathy and cerebral amyloid angiopathy, and may be associated with cognitive impairment. The relationship between CMBs and cognitive function in ischemic cerebrovascular disease remains uncertain. We, therefore, investigated the cognitive impact of CMBs in a cohort of patients with ischemic stroke or transient ischemic attack. METHODS: All patients underwent detailed and comprehensive neuropsychological testing and standardized MRI, including fluid attenuation inversion recovery, T1, T2, and gradient-recalled echo T2*-weighted sequences. CMBs, white matter changes, lacunes, and territorial cortical infarcts (defined by standardized criteria) were identified, and associations with cognition assessed. RESULTS: Three hundred twenty patients with a diagnosis of ischemic stroke or transient ischemic attack were included. Of these, 72 (22.5%) had at least 1 CMB. Of all the cognitive domains tested, only executive impairment was more prevalent in patients with CMBs than without (38% versus 25%; P=0.039). In univariate analysis, the presence of strictly lobar (but not deep) CMBs was associated with executive impairment (odds ratio, 2.49; 95% confidence interval, 1.16-5.36; P=0.019). In adjusted multivariate analyses, the presence (OR, 2.34; 95% confidence interval, 1.08-5.09; P=0.031) and number (OR, 1.33; 95% confidence interval, 1.04-1.69; P=0.022) of strictly lobar CMBs were significantly associated with executive impairment. CMBs were not associated with impairment in other cognitive domains. CONCLUSIONS: Strictly lobar CMBs are independently associated with executive dysfunction in patients with ischemic stroke or transient ischemic attack. Our findings suggest that a microangiopathy related to strictly lobar CMBs (eg, cerebral amyloid angiopathy) contributes to cognitive impairment in this population.
Authors: Saloua Akoudad; Frank J Wolters; Anand Viswanathan; Renée F de Bruijn; Aad van der Lugt; Albert Hofman; Peter J Koudstaal; M Arfan Ikram; Meike W Vernooij Journal: JAMA Neurol Date: 2016-08-01 Impact factor: 18.302
Authors: François De Guio; Eric Jouvent; Geert Jan Biessels; Sandra E Black; Carol Brayne; Christopher Chen; Charlotte Cordonnier; Frank-Eric De Leeuw; Martin Dichgans; Fergus Doubal; Marco Duering; Carole Dufouil; Emrah Duzel; Franz Fazekas; Vladimir Hachinski; M Arfan Ikram; Jennifer Linn; Paul M Matthews; Bernard Mazoyer; Vincent Mok; Bo Norrving; John T O'Brien; Leonardo Pantoni; Stefan Ropele; Perminder Sachdev; Reinhold Schmidt; Sudha Seshadri; Eric E Smith; Luciano A Sposato; Blossom Stephan; Richard H Swartz; Christophe Tzourio; Mark van Buchem; Aad van der Lugt; Robert van Oostenbrugge; Meike W Vernooij; Anand Viswanathan; David Werring; Frank Wollenweber; Joanna M Wardlaw; Hugues Chabriat Journal: J Cereb Blood Flow Metab Date: 2016-05-11 Impact factor: 6.200
Authors: Irene B Meier; Yian Gu; Vanessa A Guzaman; Anne F Wiegman; Nicole Schupf; Jennifer J Manly; José A Luchsinger; Anand Viswanathan; Sergi Martinez-Ramirez; Steven M Greenberg; Richard Mayeux; Adam M Brickman Journal: Cerebrovasc Dis Date: 2014-11-25 Impact factor: 2.762
Authors: Gianvincenzo Sparacia; Francesco Agnello; Giuseppe La Tona; Alberto Iaia; Federico Midiri; Benedetta Sparacia Journal: Neuroradiol J Date: 2017-05-02
Authors: Paul A Yates; Victor L Villemagne; Kathryn A Ellis; Patricia M Desmond; Colin L Masters; Christopher C Rowe Journal: Front Neurol Date: 2014-01-06 Impact factor: 4.003
Authors: Steven M Greenberg; Rustam Al-Shahi Salman; Geert Jan Biessels; Mark van Buchem; Charlotte Cordonnier; Jin-Moo Lee; Joan Montaner; Julie A Schneider; Eric E Smith; Meike Vernooij; David J Werring Journal: Lancet Neurol Date: 2014-02-27 Impact factor: 44.182